Ortivus (ORTI-B.ST) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies SEK Explore free reports

Ortivus (ORTI-B.ST) overview

Ortivus (ORTI-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Ortivus reported revenue of SEK 73.4m and operating profit of SEK -14.4m; the year-end share price was 1.22 SEK and market capitalisation was SEK 62.8m. Ortivus is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ortivus's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 22.4mFY 2025
Share price1.22 SEKFY 2025 year end
RevenueSEK 73.4mFY 2025
Operating profitSEK -14.4mFY 2025
Net earningsSEK -21.9mFY 2025
Market capitalisationSEK 62.8mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Ortivus

Ortivus develops and markets digital solutions for pre-hospital and ambulance care. Its MobiMed platform includes electronic patient care records, patient monitoring, fleet management, navigation and case management, and defibrillator products. The company’s business is driven by software and connected medical systems that help emergency services document care, share information, and manage operations.

Generate the Ortivus report

Ortivus is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Ortivus and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.